跳至主要内容
临床试验/ITMCTR2200005716
ITMCTR2200005716尚未招募4 期

A multicenter, randomized, controlled study of Shugan Xiaozhi Granules in the treatment of nonalcoholic fatty liver disease patients with abnormal ALT

Shenzhen TCM Hospital0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 65(—)
性别
All

入选标准

  • 1. Meet the diagnostic criteria for nonalcoholic fatty liver disease with abnormal ALT
  • 2. TCM syndrome classification is: liver and gallbladder damp-heat, phlegm blocking blood stasis
  • 3. Age 18-65 years old, no drinking history or drinking alcohol equivalent to ethanol <30 g/d for men and <20 for women

排除标准

  • 1. It is complicated with Drug-induced liver injury, autoimmune hepatitis, viral hepatitis, alcoholic liver disease, liver cancer
  • 2. It is complicated with Heart, brain, kidney, lung, blood, severe diabetic complications, thyroid dysfunction, metabolic and gastrointestinal serious primary diseases, or mental patients
  • 3. Women who are breastfeeding, pregnant or planning to become pregnant
  • 4. Abnormal transaminases greater than 5 times the upper limit of normal, and creatinine greater than the upper limit of normal

研究者

发起方
Shenzhen TCM Hospital

相似试验